In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis , Coccidioides immitis , and Histoplasma capsulatum
Open Access
- 1 June 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (6) , 1734-1736
- https://doi.org/10.1128/aac.44.6.1734-1736.2000
Abstract
The in vitro activity of voriconazole was compared to those of itraconazole and amphotericin B against the mold forms of 304 isolates of three dimorphic fungi, Blastomyces dermatitidis,Coccidioides immitis, and Histoplasma capsulatum. MICs were determined by a broth microdilution adaptation of the National Committee for Clinical Laboratory Standards M27-A procedure. RPMI 1640 medium was used for tests with voriconazole and itraconazole, whereas Antibiotic Medium 3 with 2% glucose was used for amphotericin B. Minimum fungicidal concentrations (MFCs) were also determined. Amphotericin B was active against all three dimorphic fungi, with MICs at which 90% of the isolates tested are inhibited (MIC90s) of 0.5 to 1 μg/ml. Itraconazole had MIC90s of 0.06 μg/ml for H. capsulatum, 0.125 μg/ml for B. dermatitidis, and 1 μg/ml for C. immitis. The MIC90s of voriconazole were 0.25 μg/ml for all three fungi. Amphotericin B was fungicidal for B. dermatitidis and H. capsulatum with MFCs at which 90% of strains tested are killed (MFC90s) of 0.5 and 2 μg/ml, respectively. It was less active against C. immitis, with MFCs ranging from 0.5 to >16 μg/ml. Voriconazole and itraconazole were lethal for most isolates of B. dermatitidis, with MFC50s and MFC90s of 0.125 and 4 μg/ml, respectively. Both azoles were fungicidal for some isolates of H. capsulatum, with MFC50s of 2 and 8 μg/ml for itraconazole and voriconazole, respectively; neither had a lethal effect upon C. immitis. Our results suggest that voriconazole possesses promising activity against these important human pathogens.Keywords
This publication has 28 references indexed in Scilit:
- Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermumJournal of Antimicrobial Chemotherapy, 1999
- In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and VoriconazoleAntimicrobial Agents and Chemotherapy, 1998
- In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungiJournal of Antimicrobial Chemotherapy, 1998
- Lipid Formulations of Amphotericin B: Clinical Efficacy and ToxicitiesClinical Infectious Diseases, 1998
- In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.Journal of Antimicrobial Chemotherapy, 1998
- In vitro efficacy and fungicidal activity of voriconazole againstAspergillus andFusarium speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin BJournal of Antimicrobial Chemotherapy, 1998
- Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients withCandidaFungemiaThe Journal of Infectious Diseases, 1998
- Role of Azoles in Antifungal TherapyClinical Infectious Diseases, 1996
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990